Fresenius Kabi is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $12.6B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Fresenius Kabi's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Otulfi |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Conexxence |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Bomyntra |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
Company facts: Fresenius. Each drug page lists sources for these entries. Brand sales show the size of the market, not Fresenius Kabi's share of it.